Catalyst

Slingshot members are tracking this event:

Advaxis (ADXS) Announces Clinical Hold In Axalimogene Filolisbac Phase 1/2 Combination Study With AstraZeneca’s IMFINZI (Durvalumab)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ADXS

100%
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 12, 2018
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Durvalumab, Imfinzi, Axalimogene Filolisbac, Phase 1/2